These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27904955)

  • 21. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
    Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
    Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.
    Alemany C
    Curr Oncol Rep; 2014 Feb; 16(2):367. PubMed ID: 24445499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
    Ma MK; Zamboni WC; Radomski KM; Furman WL; Santana VM; Houghton PJ; Hanna SK; Smith AK; Stewart CF
    Clin Cancer Res; 2000 Mar; 6(3):813-9. PubMed ID: 10741701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
    J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
    van der Bol JM; Mathijssen RH; Loos WJ; Friberg LE; van Schaik RH; de Jonge MJ; Planting AS; Verweij J; Sparreboom A; de Jong FA
    J Clin Oncol; 2007 Jul; 25(19):2719-26. PubMed ID: 17563393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
    Kurzrock R; Goel S; Wheler J; Hong D; Fu S; Rezai K; Morgan-Linnell SK; Urien S; Mani S; Chaudhary I; Ghalib MH; Buchbinder A; Lokiec F; Mulcahy M
    Cancer; 2012 Dec; 118(24):6144-51. PubMed ID: 22674635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal function as a predictor of irinotecan-induced neutropenia.
    de Jong FA; van der Bol JM; Mathijssen RH; van Gelder T; Wiemer EA; Sparreboom A; Verweij J
    Clin Pharmacol Ther; 2008 Aug; 84(2):254-62. PubMed ID: 18288083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
    Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
    Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
    Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
    Crona DJ; Ramirez J; Qiao W; de Graan AJ; Ratain MJ; van Schaik RH; Mathijssen RH; Rosner GL; Innocenti F
    Pharmacogenomics J; 2016 Feb; 16(1):54-9. PubMed ID: 25869015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
    Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
    Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
    Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.